6 Green Days In A Row: Tarsus Pharmaceuticals Stock Is Up 19%
Shares of Tarsus Pharmaceuticals (TARS) have closed higher in each of the last 6 sessions, a cumulative gain of 18.9%. That added about $592 million to the company’s market value, which now stands at about $3.7 billion. The stock closed at $80.28 on Friday, November 13, 11.6% below its 52-week high of $90.78 and 43.1% above its low of $56.11.
TARS Versus The S&P 500
Returns for TARS and the S&P 500 over the streak and the periods around it, all ending Friday, November 13 and including dividends:
| Return Period | TARS | S&P 500 |
|---|---|---|
| 1 Day | 4.4% | -0.4% |
| 6 Days (Current Streak) | 18.9% | 2.9% |
| 1 Month (21 Trading Days) | 13.1% | -2.3% |
| 3 Months (63 Trading Days) | 13.7% | -2.1% |
| Year To Date | -2.0% | 11.5% |
| 1 Year (252 Trading Days) | 7.3% | 11.7% |
Is This Move About Tarsus Pharmaceuticals Or The Market?
Over the same 6 trading days, the S&P 500 returned +2.9% including dividends, so the run is mostly Tarsus Pharmaceuticals’ own story rather than the market’s. Over the past three months the stock is up 13.7%, a window that includes the streak; over the other 57 sessions of that window it was down 4.4%.
Do The Fundamentals Support The Run?
On the fundamentals, revenue grew 86.3% over the last twelve months, against a median of 7.9% for S&P 500 Health Care stocks; and its operating margin is -102.3%, versus a median of 17.4%. Tarsus Pharmaceuticals does not have positive trailing earnings, so there is no meaningful price-to-earnings multiple to compare. The read is mixed: revenue growth above the median on one side, an operating loss on the other.
A climb like this is worth respecting, and worth testing. Our Guidance Momentum screen tracks the stocks whose companies just raised their own forward numbers.
One Hot Stock Is A Story. Thirty Sound Ones Are A Strategy
A streak like this earns a place on your watchlist, and it also earns a question: how much of your outcome do you want depending on one company keeping this up?
The Trefis High Quality (HQ) Portfolio answers it with breadth: roughly 30 businesses picked for consistent cash generation, strong margins, and balance-sheet strength, sized and rebalanced by rules. It has a track record of outpacing a benchmark that combines the S&P 500, the S&P MidCap 400, and the Russell 2000. Follow the story; invest in the strategy.